Clinical Trial Centralized Monitoring Shouldn’t Be Automatic, Industry Tells FDA
Executive Summary
FDA needs to provide further clarification about how “centralized” clinical trial monitoring could work as a substitute for onsite monitoring, industry commenters say as they urge FDA not to move too fast towards a “risk-based” approach.